{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:23:03Z","timestamp":1787750583108,"version":"build-2784847793"},"reference-count":77,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Drug-induced liver injury (DILI) is one of the most common adverse reactions in clinical settings, and drug hepatotoxicity is also a primary factor contributing to the suspension and withdrawal of drug development. Currently, there are no specific biomarkers available for the early diagnosis and monitoring of DILI in clinical practice. In recent years, metabolomics has emerged as a powerful tool for identifying small molecule biomarkers in DILI, owing to its unique advantages. In this article, we comprehensively reviewed the metabolomics studies related to DILI to investigate the pathophysiological changes in DILI and to assess the potential application of metabolomics in its prediction and diagnosis. Relevant literature published before 30 April 2024 was retrieved from four online databases (PubMed, EMbase, Cochrane Library, and Web of Science). Research data were systematically collected, and the metabolites involved were analyzed. Metabolic pathway analysis related to DILI was conducted using the online software MetaboAnalyst 5.0. A total of 55 studies were included, identifying significantly altered metabolic pathways and valuable metabolic biomarkers. The most frequently reported biomarkers included glycocholic acid, taurochenodeoxycholic acid, taurocholic acid, creatine, glycochenodeoxycholic acid, taurodeoxycholic acid, glycodeoxycholic acid, and\n                    <jats:italic>\u03b1<\/jats:italic>\n                    -ketoglutaric acid. The disrupted metabolic pathways were mainly related to bile acid metabolism, lipid metabolism, and the tricarboxylic acid cycle, among which bile acid metabolism showing the most prominent alterations. Lipid metabolism-related pathways included fatty acid biosynthesis, glycerophospholipid metabolism, and sphingolipid metabolism. This article provides a systematic review of metabolomics in DILI, deepening our understanding of the metabolic disturbances caused by DILI.\n                  <\/jats:p>","DOI":"10.1515\/jtim-2026-0056","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:55:36Z","timestamp":1786521336000},"page":"547-562","source":"Crossref","is-referenced-by-count":0,"title":["Application of metabolomics in drug-induced liver injury: A systematic review"],"prefix":"10.1515","volume":"14","author":[{"given":"Xiaoyan","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Peking University Third Hospital , Beijing , China"},{"name":"Department of Pharmacy, Zhengzhou Central Hospital Affiliated to Zhengzhou University , Zhengzhou , Henan Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[{"name":"School of pharmacy, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Third Hospital , Beijing , China"},{"name":"Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Third Hospital , Beijing , China"},{"name":"Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhengzhou Central Hospital Affiliated to Zhengzhou University , Zhengzhou , Henan Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhengzhou Central Hospital Affiliated to Zhengzhou University , Zhengzhou , Henan Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhengzhou Central Hospital Affiliated to Zhengzhou University , Zhengzhou , Henan Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhengzhou Central Hospital Affiliated to Zhengzhou University , Zhengzhou , Henan Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7554-6823","authenticated-orcid":false,"given":"Xin","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Third Hospital , Beijing , China"},{"name":"Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4968-6045","authenticated-orcid":false,"given":"Libo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University Third Hospital , Beijing , China"},{"name":"Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"2026082612595947341_j_jtim-2026-0056_ref_001","doi-asserted-by":"crossref","unstructured":"Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HHJ, Goldering CE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov 2020;19:131\u2013148.","DOI":"10.1038\/s41573-019-0048-x"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_002","doi-asserted-by":"crossref","unstructured":"Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731\u2013739.","DOI":"10.1056\/NEJMra052270"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_003","doi-asserted-by":"crossref","unstructured":"Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci 2021;22:2954.","DOI":"10.3390\/ijms22062954"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_004","doi-asserted-by":"crossref","unstructured":"Teschke R, Danan G. Advances in idiosyncratic drug-induced liver injury issues: new clinical and mechanistic analysis due to rousset uclaf causality assessment method use. Int J Mol Sci 2023;24:10855.","DOI":"10.3390\/ijms241310855"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_005","doi-asserted-by":"crossref","unstructured":"Chu M-T, Chang WC, Pao S-C, Hung S-I. Delayed drug hypersensitivity reactions: molecular recognition, genetic susceptibility, and immune mediators. Biomedicines 2023;11:177.","DOI":"10.3390\/biomedicines11010177"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_006","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnsson HK, Bj\u00f6rnsson ES. Review of human risk factors for idiosyncratic drug-induced liver injury: latest advances and future goals. Expert Opin Drug Metab Toxicol 2023;19:969\u2013977.","DOI":"10.1080\/17425255.2023.2288260"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_007","doi-asserted-by":"crossref","unstructured":"Gu R, Liang A, Liao G, To I, Shehu A, Ma X. Roles of cofactors in drug-induced liver injury: drug metabolism and beyond. Drug Metab Dispos 2022;50:646\u2013654.","DOI":"10.1124\/dmd.121.000457"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_008","doi-asserted-by":"crossref","unstructured":"Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331\u20131336.","DOI":"10.1016\/0895-4356(93)90102-7"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_009","doi-asserted-by":"crossref","unstructured":"Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci 2015;17:14.","DOI":"10.3390\/ijms17010014"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_010","unstructured":"Mao YM. [Standardize the diagnosis and treatment of drug-induced liver injury, and strengthen clinical and translational research]. Zhonghua Gan Zang Bing Za Zhi 2023;31:337\u2013338."},{"key":"2026082612595947341_j_jtim-2026-0056_ref_011","doi-asserted-by":"crossref","unstructured":"Moreno-Torres M, Quint\u00e1s G, Castell JV. The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment. Metabolites 2022;12:564.","DOI":"10.3390\/metabo12060564"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_012","doi-asserted-by":"crossref","unstructured":"Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal 2015;113:108\u2013120.","DOI":"10.1016\/j.jpba.2014.12.017"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_013","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;74:790\u2013799.","DOI":"10.1136\/bmj.n71"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_014","doi-asserted-by":"crossref","unstructured":"Monte AA, Vest A, Reisz JA, Berninzoni D, Hart C, Dylla L, et al. A multi-omic mosaic model of acetaminophen induced alanine aminotransferase elevation. J Med Toxicol 2023;19:255\u2013261.","DOI":"10.1007\/s13181-023-00951-5"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_015","doi-asserted-by":"crossref","unstructured":"Gorrochategui E, Le Vee M, Selmi H, G\u00e9rard A, Chaker J, Kraiss AM, et al. High-resolution mass spectrometry identifies delayed biomarkers for improved precision in acetaminophen\/paracetamol human biomonitoring. Environ Int 2023;181:108299.","DOI":"10.1016\/j.envint.2023.108299"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_016","doi-asserted-by":"crossref","unstructured":"Chiew AL, Isbister GK, Stathakis P, Isoardi KZ, Page C, Riss K, et al. Acetaminophen metabolites on presentation following an acute acetaminophen overdose (ATOM-7). Clin Pharma And Therapeutics 2023;113:1304\u20131314.","DOI":"10.1002\/cpt.2888"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_017","doi-asserted-by":"crossref","unstructured":"Sonn BJ, Heard KJ, Heard SM, D'Alessandro A, Reynolds KM, Dart RC, et al. Metabolomic markers predictive of hepatic adaptation to therapeutic dosing of acetaminophen. Clin Toxicol 2022;60:221\u2013230.","DOI":"10.1080\/15563650.2021.1925686"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_018","doi-asserted-by":"crossref","unstructured":"Dear JW, Ng ML, Bateman DN, Leroy Sivappiragasam P, Choi H, Khoo BB, et al. A metabolomic analysis of thiol response for standard and modified N-acetyl cysteine treatment regimens in patients with acetaminophen overdose. Clin Transl Sci 2021;14:1476\u20131489.","DOI":"10.1111\/cts.13009"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_019","doi-asserted-by":"crossref","unstructured":"Schnackenberg LK, Sun J, Bhattacharyya S, Gill P, James LP, Beger RD. Metabolomics Analysis of Urine Samples from Children after Acetaminophen Overdose. Metabolites 2017;7:46.","DOI":"10.3390\/metabo7030046"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_020","doi-asserted-by":"crossref","unstructured":"Gray N, Zia R, King A, Patel VC, Wendon J, McPhail MJW, et al. High-speed quantitative UPLC-MS analysis of multiple amines in human plasma and serum via precolumn derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate: application to acetaminophen-induced liver failure. Anal Chem 2017;89:2478\u20132487.","DOI":"10.1021\/acs.analchem.6b04623"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_021","doi-asserted-by":"crossref","unstructured":"Bhattacharyya S, Pence L, Yan K, Gill P, Luo C, Letzig LG, et al. Targeted metabolomic profiling indicates structure-based perturbations in serum phospholipids in children with acetaminophen overdose. Toxicol Rep 2016;3:747\u2013755.","DOI":"10.1016\/j.toxrep.2016.08.004"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_022","doi-asserted-by":"crossref","unstructured":"James L, Yan K, Pence L, Simpson P, Bhattacharyya S, Gill P, et al. Comparison of Bile Acids and Acetaminophen Protein Adducts in Children and Adolescents with Acetaminophen Toxicity. PLoS One 2015;10:e0131010.","DOI":"10.1371\/journal.pone.0131010"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_023","doi-asserted-by":"crossref","unstructured":"Bhattacharyya S, Yan K, Pence L, Simpson PM, Gill P, Letzig LG, et al. Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children. Biomark Med 2014;8:147\u2013159.","DOI":"10.2217\/bmm.13.150"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_024","doi-asserted-by":"crossref","unstructured":"McGill MR, Li F, Sharpe MR, Williams CD, Curry SC, Ma X, et al. Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans. Arch Toxicol 2014;88:391\u2013401.","DOI":"10.1007\/s00204-013-1118-1"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_025","doi-asserted-by":"crossref","unstructured":"Woolbright BL, McGill MR, Staggs VS, Winefield RD, Gholami P, Olyae M, et al. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. Toxicol Sci 2014;142:436\u2013444.","DOI":"10.1093\/toxsci\/kfu195"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_026","doi-asserted-by":"crossref","unstructured":"Kim JW, Ryu SH, Kim S, Lee HW, Lim MS, Seong SJ, et al. Pattern recognition analysis for hepatotoxicity induced by acetaminophen using plasma and urinary 1H NMR-based metabolomics in humans. Anal Chem 2013;85:11326\u201311334.","DOI":"10.1021\/ac402390q"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_027","doi-asserted-by":"crossref","unstructured":"Jetten MJ, Gaj S, Ruiz-Aracama A, de Kok TM, van Delft JH, Lommen A, et al. Omics analysis of low dose acetaminophen intake demonstrates novel response pathways in humans. Toxicol Appl Pharmacol 2012;259:320\u2013328.","DOI":"10.1016\/j.taap.2012.01.009"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_028","doi-asserted-by":"crossref","unstructured":"Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 2010;88:45\u201351.","DOI":"10.1038\/clpt.2009.240"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_029","doi-asserted-by":"crossref","unstructured":"Fannin RD, Russo M, O'Connell TM, Gerrish K, Winnike JH, Macdonald J, et al. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology 2010;51:227\u2013236.","DOI":"10.1002\/hep.23330"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_030","doi-asserted-by":"crossref","unstructured":"Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009;106:14728\u201314733.","DOI":"10.1073\/pnas.0904489106"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_031","doi-asserted-by":"crossref","unstructured":"Xiong A, Lu L, Jiang K, Wang X, Chen Y, Wang X, et al. Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Arch Toxicol 2024;98:2557\u20132576.","DOI":"10.1007\/s00204-024-03762-x"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_032","doi-asserted-by":"crossref","unstructured":"Hu Y, Wang C, Fei Z, Zhou M, Yu H, Sun Z. Potential biomarkers screening of Polygonum multiflorum Radix-induced liver injury based on metabonomics analysis of clinical samples. J Ethnopharmacol 2023;308:116217.","DOI":"10.1016\/j.jep.2023.116217"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_033","doi-asserted-by":"crossref","unstructured":"Huang Y, Zhao X, Zhang ZT, Chen SS, Li SS, Shi Z, et al. Metabolomics profiling and diagnosis biomarkers searching for drug-induced liver injury implicated to Polygonum multiflorum: a cross-sectional cohort study. Front Med 2020;7:592434.","DOI":"10.3389\/fmed.2020.592434"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_034","doi-asserted-by":"crossref","unstructured":"Zhang L, Niu M, Wei AW, Tang JF, Tu C, Bai ZF, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum. Arch Toxicol 2020;94:245\u2013256.","DOI":"10.1007\/s00204-019-02595-3"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_035","doi-asserted-by":"crossref","unstructured":"Wang J, Ma Z, Niu M, Zhu Y, Liang Q, Zhao Y, et al. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med 2015;9:457\u2013467.","DOI":"10.1007\/s11684-015-0417-8"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_036","doi-asserted-by":"crossref","unstructured":"Tian M, Yan J, Zhang H, Wei Y, Zhang M, Rao Z, et al. Screening and validation of biomarkers for cadmium-induced liver injury based on targeted bile acid metabolomics. Environ Pollut 2022;300:118837.","DOI":"10.1016\/j.envpol.2022.118837"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_037","doi-asserted-by":"crossref","unstructured":"Guardiola JJ, Beier JJ, Falkner KC, Wheeler B, McClain CJ, Cave M. Occupational exposures at a polyvinyl chloride production facility are associated with significant changes to the plasma metabolome. Toxicol Appl Pharmacol 2016;313:47\u201356.","DOI":"10.1016\/j.taap.2016.10.001"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_038","doi-asserted-by":"crossref","unstructured":"Wang H, Xi S, Liu Z, Yang Y, Zheng Q, Wang F, et al. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Environ Toxicol 2011;28:267\u2013275.","DOI":"10.1002\/tox.20717"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_039","doi-asserted-by":"crossref","unstructured":"Chiang Y-H, Cheng C-N, Chuang P-J, Chen Y-C, Chen YJ, Kuo C-H, et al. Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics. Int J Antimicrob Agents 2024;63:107028.","DOI":"10.1016\/j.ijantimicag.2023.107028"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_040","doi-asserted-by":"crossref","unstructured":"Wang MG, Wu SQ, Zhang MM, He JQ. Plasma metabolomic and lipidomic alterations associated with anti-tuberculosis drug-induced liver injury. Front Pharmacol 2022;13:1044808.","DOI":"10.3389\/fphar.2022.1044808"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_041","doi-asserted-by":"crossref","unstructured":"Wang MG, Wu SQ, Zhang MM, He JQ. Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: a prospective study. Front Immunol 2022;13:1002126.","DOI":"10.3389\/fimmu.2022.1002126"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_042","doi-asserted-by":"crossref","unstructured":"Wu S, Wang M, Zhang M, He JQ. Metabolomics and microbiomes for discovering biomarkers of antituberculosis drugs-induced hepatotoxicity. Arch Biochem Biophys 2022;716:109118.","DOI":"10.1016\/j.abb.2022.109118"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_043","unstructured":"Helsley RN, Miyata T, Kadam A, Varadharajan V, Sangwan N, Huang EC, et al. Gut microbial trimethylamine is elevated in alcohol-associated hepatitis and contributes to ethanol-induced liver injury in mice. eLife 2022;11:e76554."},{"key":"2026082612595947341_j_jtim-2026-0056_ref_044","doi-asserted-by":"crossref","unstructured":"Li X, Yang J, Jin S, Dai Y, Fan Y, Fan X, et al. Mechanistic examination of methimazole-induced hepatotoxicity in patients with Grave's disease: a metabolomic approach. Arch Toxicol 2020;94:231\u2013244.","DOI":"10.1007\/s00204-019-02618-z"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_045","doi-asserted-by":"crossref","unstructured":"Wu S-L, Cheng C-N, Wang CC, Lin SW, Kuo C-H. Metabolomics analysis of plasma reveals voriconazole-induced hepatotoxicity is associated with oxidative stress. Toxicol Appl Pharmacol 2020;403:115157.","DOI":"10.1016\/j.taap.2020.115157"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_046","doi-asserted-by":"crossref","unstructured":"Cao J, Mi Y, Shi C, Bian Y, Huang C, Ye Z, et al. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform. Biochem Biophys Res Commun 2018;497:485\u2013491.","DOI":"10.1016\/j.bbrc.2018.02.030"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_047","doi-asserted-by":"crossref","unstructured":"Lee J, Ji SC, Kim B, Yi S, Shin KH, Cho JY, et al. Exploration of Biomarkers for Amoxicillin\/Clavulanate-Induced Liver Injury: Multi-Omics Approaches. Clin Transl Sci 2017;10:163\u2013171.","DOI":"10.1111\/cts.12425"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_048","doi-asserted-by":"crossref","unstructured":"Huo T, Chen X, Lu X, Qu L, Liu Y, Cai S. An effective assessment of valproate sodium-induced hepatotoxicity with UPLC-MS and 1HNMR-based metabonomics approach. J Chromatogr B 2014;969:109\u2013116.","DOI":"10.1016\/j.jchromb.2014.08.011"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_049","doi-asserted-by":"crossref","unstructured":"Andersson U, Lindberg J, Wang S, Balasubramanian R, Marcusson-Stahl M, Hannula M, et al. A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers 2009;14:572\u2013586.","DOI":"10.3109\/13547500903261354"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_050","doi-asserted-by":"crossref","unstructured":"Moreno-Torres M, Quint\u00e1s G, Mart\u00ednez-Sena T, Jover R, Castell JV. Exploring individual variability in drug-induced liver injury (DILI) responses through metabolomic analysis. Int J Mol Sci 2024;25:3003.","DOI":"10.3390\/ijms25053003"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_051","doi-asserted-by":"crossref","unstructured":"He K, Liu M, Wang Q, Chen S, Guo X. Combined analysis of 16S rDNA sequencing and metabolomics to find biomarkers of drug-induced liver injury. Sci Rep 2023;13:15138.","DOI":"10.1038\/s41598-023-42312-w"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_052","doi-asserted-by":"crossref","unstructured":"And\u00fajar-Vera F, Al\u00e9s-Palmer ML, Mu\u00f1oz-de-Rueda P, Iglesias-Baena I, Ocete-Hita E. Metabolomic analysis of pediatric patients with idiosyncratic drug-induced liver injury according to the updated RUCAM. Int J Mol Sci 2023;24:13562.","DOI":"10.3390\/ijms241713562"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_053","doi-asserted-by":"crossref","unstructured":"Zhao S, Fu H, Zhou T, Cai M, Huang Y, Gan Q, et al. Alteration of bile acids and omega-6 PUFAs are correlated with the progression and prognosis of drug-induced liver injury. Front Immunol 2022;13:772368.","DOI":"10.3389\/fimmu.2022.772368"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_054","doi-asserted-by":"crossref","unstructured":"He X, Zhou MX, Cheng C, Li SS, Gao Y, Ma ZT, et al. Metabolomic profiling for histologically fibrotic stage in chronic drug-induced liver injury. Front Pharmacol 2022;13:896198.","DOI":"10.3389\/fphar.2022.896198"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_055","doi-asserted-by":"crossref","unstructured":"Han YZ, Ma ZT, Zhou MX, Niu M, Zhao X, Guo YM, et al. Metabolomic profiling for drug-induced liver injury with autoantibodies. Int Immunopharmacol. 2022;111:109084.","DOI":"10.1016\/j.intimp.2022.109084"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_056","doi-asserted-by":"crossref","unstructured":"Tian X, Wang Y, Lu Y, Wu B, Chen S, Du J, et al. Metabolic regulation of cholestatic liver injury by D-2-hydroxyglutarate with the modulation of hepatic microenvironment and the mammalian target of rapamycin signaling. Cell Death Dis. 2022;13:1001.","DOI":"10.1038\/s41419-022-05450-z"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_057","doi-asserted-by":"crossref","unstructured":"Xie Z, Zhang L, Chen E, Lu J, Xiao L, Liu Q, et al. Targeted metabolomics analysis of bile acids in patients with idiosyncratic drug-induced liver injury. Metabolites 2021;11:852.","DOI":"10.3390\/metabo11120852"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_058","doi-asserted-by":"crossref","unstructured":"Chen SS, Huang Y, Guo YM, Li SS, Shi Z, Niu M, et al. Serum metabolomic analysis of chronic drug-induced liver injury with or without cirrhosis. Front Med 2021;8:640799.","DOI":"10.3389\/fmed.2021.640799"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_059","doi-asserted-by":"crossref","unstructured":"Quint\u00e1s G, Mart\u00ednez-Sena T, Conde I, Pareja Ibars E, Kleinjans J, Castell JV. Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes. Arch Toxicol 2021;95:3049\u20133062.","DOI":"10.1007\/s00204-021-03114-z"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_060","doi-asserted-by":"crossref","unstructured":"Saito K, Kagawa T, Tsuji K, Kumagai Y, Sato K, Sakisaka S, et al. Plasma lipid profiling of three types of drug-induced liver injury in Japanese patients: a preliminary study. Metabolites 2020;10:355.","DOI":"10.3390\/metabo10090355"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_061","doi-asserted-by":"crossref","unstructured":"Ma Z, Wang X, Yin P, Wu R, Zhou L, Xu G, et al. Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. Medicine 2019;98:e16717.","DOI":"10.1097\/MD.0000000000016717"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_062","doi-asserted-by":"crossref","unstructured":"Xie Z, Chen E, Ouyang X, Xu X, Ma S, Ji F, et al. Metabolomics and cytokine analysis for identification of severe drug-induced liver injury. J Proteome Res 2019;18:2514\u20132524.","DOI":"10.1021\/acs.jproteome.9b00047"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_063","doi-asserted-by":"crossref","unstructured":"Wang X, Jing J, Niu M, Wei L, Liu X, Tu C, et al. Metabolomic profiling and biomarkers of drug-induced liver injury with pre-existing alcoholic liver disease. Sci Sin-Vitae 2019;49:749\u2013760.","DOI":"10.1360\/N052018-00291"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_064","unstructured":"Wei LG, , Wang XH, Niu M, Liu XY, Tu C, Zhou YY, et al. Metabolomic screening for diagnostic biomarkers of drug-induced chronic liver injury related cirrhosis. Acta Pharmaceutica Sinica 2019;54:1449\u20131456."},{"key":"2026082612595947341_j_jtim-2026-0056_ref_065","unstructured":"An ZL, Shi C, Zhao R, Li PF, Liu LH. Ultra High Performance Liquid Chromatography Coupled with Q Exactive Hybrid Quadrupole-orbitrap Mass Spectrometry for Serumal Metabonomics Study of Drug-induced Liver Injury in Patients. Chin J Anal Chem 2015;43:1408\u20131414."},{"key":"2026082612595947341_j_jtim-2026-0056_ref_066","doi-asserted-by":"crossref","unstructured":"Wang JB, Pu SB, Sun Y, Li ZF, Niu M, Yan XZ, et al. Metabolomic profiling of autoimmune hepatitis: the diagnostic utility of nuclear magnetic resonance spectroscopy. J Proteome Res 2014;13:3792\u20133801.","DOI":"10.1021\/pr500462f"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_067","unstructured":"Li X, Lian J, Wang Y, Huang J. A serum metabonomics study on drug induced liver injury by UPLC coupled with Q-TOF mass spectrometry. Chin J Microecol 2013;25:625\u2013629."},{"key":"2026082612595947341_j_jtim-2026-0056_ref_068","doi-asserted-by":"crossref","unstructured":"Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, et al. Serum metabolomics reveals gamma-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 2011;55:896\u2013905.","DOI":"10.1016\/j.jhep.2011.01.031"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_069","doi-asserted-by":"crossref","unstructured":"Sundaram V, Bj\u00f6rnsson ES. Drug-induced cholestasis. Hepatol Commun 2017;1:726\u2013735.","DOI":"10.1002\/hep4.1088"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_070","doi-asserted-by":"crossref","unstructured":"Garcia-Canaveras JC, Donato MT, Castell JV, Lahoz A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res 2012;53:2231\u20132241.","DOI":"10.1194\/jlr.D028803"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_071","doi-asserted-by":"crossref","unstructured":"Sangaraju D, Shi Y, Van Parys M, Ray A, Walker A, Caminiti R, et al. Robust and comprehensive targeted metabolomics method for quantification of 50 different primary, secondary, and sulfated bile acids in multiple biological species (human, monkey, rabbit, dog, and rat) and matrices (plasma and urine) using liquid chromatography high resolution mass spectrometry (LC-HRMS) analysis. J Am Soc Mass Spectrom 2021;32:2033\u20132049.","DOI":"10.1021\/jasms.0c00435"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_072","doi-asserted-by":"crossref","unstructured":"Manzotti C, Casazza G, Stimac T, Nikolova D, Gluud C. Total serum bile acids or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev 2019;7:Cd012546.","DOI":"10.1002\/14651858.CD012546.pub2"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_073","doi-asserted-by":"crossref","unstructured":"Huang WM, Gowda M, Donnelly JG. Bile acid ratio in diagnosis of intrahepatic cholestasis of pregnancy. Am J Perinatol 2009;26:291\u2013294.","DOI":"10.1055\/s-0028-1103158"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_074","doi-asserted-by":"crossref","unstructured":"Karlsson E, Forngren B, Kolmert J, Wahlstr\u00f6m E, Gustafsson I, D\u00f6nnies P, et al. Bile acid profiling as an investigative tool for liver function and biliary toxicity. Toxicol Lett 2012;211:S47.","DOI":"10.1016\/j.toxlet.2012.03.191"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_075","doi-asserted-by":"crossref","unstructured":"Meunier L, Larrey D. Drug-induced liver injury: biomarkers, requirements, candidates, and validation. Front Pharmacol 2019;10:1482.","DOI":"10.3389\/fphar.2019.01482"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_076","doi-asserted-by":"crossref","unstructured":"Mucke VT, Thomas D, Mucke MM, Waidmann O, Zeuzem S, Sarrazin C, et al. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. Liver Int 2019;39:2174\u20132183.","DOI":"10.1111\/liv.14178"},{"key":"2026082612595947341_j_jtim-2026-0056_ref_077","doi-asserted-by":"crossref","unstructured":"Li C, Ming Y, Wang Z, Xu Q, Yao L, Xu D, et al. GADD45alpha alleviates acetaminophen-induced hepatotoxicity by promoting AMPK activation. Cell Mol Life Sci 2019;76:129\u2013145.","DOI":"10.1007\/s00018-018-2912-y"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0056\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0056\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:02:23Z","timestamp":1787749343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0056\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":77,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,8,26]]}},"alternative-id":["10.1515\/jtim-2026-0056"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2026-0056","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}